• The goal of this clinical research study is to learn the safety of adding 3 different dose-levels of Sutent® (sunitinib malate) to a combination of hormone therapy and radiation in patients with prostate cancer. [ Time Frame: 2 Years ] [ Designated as safety issue: Yes ]
  

Inclusion Criteria:

1. Adenocarcinoma of the prostate with the following high-risk features are eligible: cT2c (palpable disease on digital rectal examination in both lobes) and Gleason Grade 7 (4+3) or higher with any PSA OR T3 or T4 disease of any Gleason Grade
2. Patients must have no evidence of metastatic disease by clinical and radiological staging including Chest X-ray, Bone scan and CT Scan of the Abdomen and Pelvis.
3. ECOG Performance Status 0-1
4. Calculated Creatinine clearance > 35cc/min, Absolute neutrophil count > 1,500/mm^3, Platelets >/= 100,000/mm^3, AST/ALT < 2.5 x UNL, Total bilirubin WNL.
5. No standard contraindications to radiation therapy including prior radiation therapy, inflammatory bowel disease and collagen vascular disease.
6. Patients must be at least 18 years of age

Exclusion Criteria:

1. Prior VEGFR/PDGFR inhibitor or other investigational therapy.
2. Inability to take oral medication
3. Uncontrolled hypertension (blood pressure > 140/90 mm Hg despite optimal medical therapy), Left Ventricular Ejection Fraction </= 40%, symptomatic congestive heart failure or symptomatic ischemic heart disease, deep venous thrombosis or pulmonary embolism in the last 12 months.
4. Known human immunodeficiency virus infection, alcoholism, chronic active hepatitis or liver cirrhosis